Anavex Life Sciences Corp (STU:12X1)
€ 8.512 1.462 (20.74%) Market Cap: 724.16 Mil Enterprise Value: 594.65 Mil PE Ratio: 0 PB Ratio: 5.98 GF Score: 40/100

Q3 2019 Anavex Life Sciences Corp Earnings Call Transcript

Aug 07, 2019 / 08:30PM GMT
Release Date Price: €2.2 (+7.84%)
Operator

Welcome to the Anavex Life Sciences Fiscal 2019 Third Quarter Financial Results Conference Call. As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Clint Tomlinson. Please go ahead.

Clint Tomlinson
Anavex Life Sciences Corp. - Executive

Thank you, and good afternoon, everyone. We appreciate you joining us today for Anavex Life Sciences conference call and webcast. Our agenda is to review the company's financial results for the third quarter of fiscal 2019 and provide a clinical study update. The taped replay of this call will be available approximately 2 hours after the call's conclusion and will remain available for 1 month. The call will also be available for replay on Anavex' website, www.anavex.com.

With us today is Dr. Christopher Missling, President and Chief Executive Officer; and Sandra Boenisch, Principal Financial Officer. Dr. Missling and Ms. Boenisch will make prepared remarks and then we will take questions

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot